吸入器设备在新发轻度喘中的有效性:一个随机盲目的多中心试验
1Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Rd, Shanghai, 200080, China.
Advances in therapy
|June 11, 2025
概括
吸入性皮质类固醇压力计量剂量吸入器 (ICS-pMDI) 在4周内改善了轻度喘患者的大小呼吸道功能. ICS-pMDI显示了与干粉吸入器 (ICS-DPI) 相比的症状控制和炎症减轻.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 低剂量吸入性皮质类固醇 (ICS) 是轻度支气管喘的标准.
- 压力计量剂量吸入器 (pMDI) 与干粉吸入器 (DPI) 在轻度喘中的有效性不如中度至重度病例的有效性.
研究的目的:
- 评估和比较ICS-pMDI与ICS-DPI在新诊断患有轻度喘的患者中的疗效.
主要方法:
- 一项为期4周的多中心随机研究,涉及156名新诊断轻度喘患者.
- 参与者接受了ICS-pMDI或ICS-DPI.
- 评估包括肺功能 (FEV1,FVC,FEF50%,FEF25-75%),喘控制测试 (ACT) 评分和血液中乙酸氨基细胞 (EOS) 计数.
主要成果:
- 与ICS-DPI相比,ICS-pMDI显著改善了大气道参数 (FEV1,FVC) 和小气道功能 (FEF50%,FEF25-75%).
- 使用ICS-pMDI观察到FEV1的绝对改善较大,特别是在基线小气道功能障碍 (SAD) 或EOS升高的患者中.
- 两种类型的吸入器都在ACT得分,EOS减少,恶化率和不良事件中表现出相似的改善.
结论:
- 4周的ICS-pMDI治疗有效地改善了新诊断的轻度喘中的大和小气道功能.
- ICS-pMDI提供与ICS-DPI相似的症状控制和炎症降低,具有类似的安全性.
- 基线SAD,高EOS水平和FEV1可逆性可能预测ICS-pMDI在增强气道功能的有效性.
相关概念视频
01:23Inhaled Medications
239
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
239
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
235
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
235
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
226
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
226
01:19Antiasthma Drugs: Leukotriene Modifiers
249
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
249